Thromboangiitis obliterans

Summary

Thromboangiitis obliterans (MONDO:0008889) is a disease and 13 clinical trials. Top therapeutic interventions include bosentan and selexipag. A subtype of peripheral vascular disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-5 / 10 000 (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 17
• Clinical trials: 13

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-5 / 10 000	16	Worldwide	Validated
Point prevalence	1-5 / 10 000	10	Europe	Validated

Signs & symptoms

Clinical features (HPO)

17 HPO clinical features (Orphanet curated; top 17 by frequency):

HPO ID	Term	Frequency
HP:0000763	Sensory neuropathy	Very frequent (80-99%)
HP:0002633	Vasculitis	Very frequent (80-99%)
HP:0004420	Arterial thrombosis	Very frequent (80-99%)
HP:0100758	Gangrene	Very frequent (80-99%)
HP:0200042	Skin ulcer	Very frequent (80-99%)
HP:0001063	Acrocyanosis	Frequent (30-79%)
HP:0002829	Arthralgia	Frequent (30-79%)
HP:0003401	Paresthesia	Frequent (30-79%)
HP:0004417	Intermittent claudication	Frequent (30-79%)
HP:0030880	Raynaud phenomenon	Frequent (30-79%)
HP:0033402	Digital ischemia	Frequent (30-79%)
HP:0033505	Livedo reticularis	Frequent (30-79%)
HP:0000975	Hyperhidrosis	Occasional (5-29%)
HP:0002638	Superficial thrombophlebitis	Occasional (5-29%)
HP:0031006	Acroparesthesia	Occasional (5-29%)
HP:0100785	Insomnia	Occasional (5-29%)
HP:0025324	Arterial occlusion	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	thromboangiitis obliterans
Mondo ID	MONDO:0008889
EFO	EFO:1001211
MeSH	D013919
OMIM	211480
Orphanet	36258
DOID	DOID:12918
ICD-10-CM	I73.1
ICD-11	1000683110
NCIT	C35070
SNOMED CT	52403007
UMLS	C0040021
MedGen	21531
GARD	0005969
MedDRA	10043540
NORD	880
Is cancer (heuristic)	no

Also known as: Buerger’s Disease · Buerger’s disease · inflammatory occlusive peripheral vascular disease · occlusive peripheral vascular disease · TAO · thromboangiitis obliterans · thromboangiitis obliterans [Buerger’s disease]

Disease family

This is a subtype of peripheral vascular disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › peripheral vascular disease › thromboangiitis obliterans

Related subtypes (10): diabetic peripheral angiopathy, telangiectasis, priapism, intermittent vascular claudication, peripheral arterial disease, mesenteric vascular occlusion, Raynaud disease, erythromelalgia, May-Thurner syndrome, livedo reticularis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE1/PHASE2	2
PHASE2	2
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05854615	PHASE4	RECRUITING	Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger’s Disease
NCT01446055	PHASE1/PHASE2	UNKNOWN	Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
NCT01484574	PHASE2	COMPLETED	A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
NCT02501018	PHASE2	COMPLETED	Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
NCT02864654	PHASE1/PHASE2	UNKNOWN	Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
NCT07215923	PHASE1	RECRUITING	A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
NCT07023965	Not specified	ENROLLING_BY_INVITATION	Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT01064206	Not specified	COMPLETED	ADDICTAO: Psychological and Addictive Profile of Patients With Buerger’s Disease
NCT01302015	Not specified	COMPLETED	Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger’s Disease
NCT01447550	Not specified	COMPLETED	Treatment of Thromboangiitis Obliterans (Buerguer’s Disease) With Bosentan
NCT02089828	Not specified	UNKNOWN	Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
NCT02128750	Not specified	COMPLETED	Contrast Enhanced Ultrasound and Muscle
NCT04914247	Not specified	APPROVED_FOR_MARKETING	Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger’s Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOSENTAN	4	1
SELEXIPAG	4	1